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Abstract 
A 25-year-old male patient presented to our Ear, Nose and Throat clinic with a history of 
nausea, vomiting, headache, vertigo and weight loss of 5 kg over the preceding 3 
months. An enlarged cervical lymph node was detected at clinical examination. Lymph 
node biopsy showed nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL, 
nodular paragranuloma). Because of the neurological symptoms a cerebral MRI scan was 
performed and revealed an intense perivascular, bilateral, contrast-medium enhancing 
lesion of the temporal lobes suggestive of cerebral vasculitis. Cerebrospinal fluid analysis 
showed an increased number of mononuclear cells, but there was no indication for 
neurotropic viral or bacterial infections. EEG revealed a left temporal epileptic focus, and 
anti-epileptic therapy was initiated. NLPHL was treated with 2 cycles of ABVD 
chemotherapy and 20 Gy involved-field radiotherapy. Steroid therapy (prednisone 100 
mg q.d.) for the presumed paraneoplastic neurological manifestation was started 1 week 
before chemotherapy and led to the rapid disappearance of complaints. Because of 
renewed onset of nausea and vertigo after 3 weeks of treatment with ABVD 
chemotherapy and 4 weeks of treatment with steroids, a follow-up brain MRI and EEG 
were performed and demonstrated complete disappearance of the ‘vasculitic’ changes 
without additional pathologic findings. Five months after therapy, the patient is without 
neurological symptoms and a PET-CT showed a complete remission. This case is a unique 
example of paraneoplastic central nervous system (CNS) involvement in a patient with  
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newly diagnosed NLPHL. We present a review of the literature on paraneoplastic CNS 
symptoms in Hodgkin’s lymphoma. 
Background 
Direct central nervous system (CNS) involvement in Hodgkin’s lymphoma is 
extremely rare with an incidence of approximately 0.02% [1], though primary 
manifestations of Hodgkin’s lymphoma in meninges [2], cerebral fluid [3] or the brain 
parenchyma [4] are known. Cerebral involvement as CNS-Hodgkin’s lymphoma is 
described in patients with former chronic lymphatic leukemia as a Richter transformation 
[5]. 
CNS manifestations, such as paraneoplastic cerebellar degeneration (PCD) in the 
presence of antibodies (i.e. anti-Tr or anti-mGluR1) against antigens in Purkinje cells, are 
well known paraneoplastic manifestations of lymphomas [6, 7]. Suggested therapies are 
steroids, intravenous immunoglobulin and plasmapheresis [6]. Clinical outcomes differ 
but are usually poor with permanent neurological sequel. 
Further, autoimmune disorders such as vasculitis, in particular granulomatous angiitis, 
have been described as complications in patients with Hodgkin’s lymphoma. Small and 
middle-sized vessels of the brain can be affected in the CNS; this was first described in 
1957 by Reich [8]. In Hodgkin’s lymphoma, a case series containing histology and clinical 
course of 10 patients has been published [9]. 
Case Presentation 
A 25-year-old male patient presented to our Ear, Nose and Throat clinic complaining of nausea 
lasting for 3 months, vertigo, headache and weight loss of 5 kg due to repetitive vomiting. Further 
examination demonstrated an enlarged cervical lymph node on level V. Extirpation of the node was 
performed and histology showed nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL, 
nodular paragranuloma) (fig. 1a–d). Further examination with PET (fig. 2), and bone marrow 
aspiration and biopsy defined stage II disease. 
Because of the neurological symptoms (nausea, vertigo and headache) cerebral MRI was performed 
and demonstrated intense perivascular, bilateral infiltration of the temporal lobes suspicious of 
vasculitis (fig. 3). Cerebrospinal fluid (CSF) analysis showed an increased number of mononuclear cells, 
but there was no indication for neurotropic viral or bacterial infections. CSF cytology and 
immunophenotyping demonstrated no abnormal neoplastic findings. Specific onconeural antibodies 
(anti-Hu, anti-Yo, anti-Ri, anti-CV2, anti-amphiphysin, anti-Ma1, anti-Ma2/Ta, anti-Tr) were negative. 
EEG suggested a left temporal epileptic focus. Anti-epileptic therapy with levetiracetam and lamotrigine 
was started. For therapy of suspected cerebral vasculitis, steroid therapy was initiated with 100 mg 
prednisone q.d., with tapering of the dose by 50% every 5 days. The patient was discharged from the 
hospital and outpatient chemotherapy with 2 cycles of ABVD (adriamycin, bleomycin, vinblastine and 
dacarabazine) was started. Within the second cycle of chemotherapy the patient developed a bleomycin 
pneumopathy and bleomycin was therefore omitted from further treatment. After termination of 2 
cycles of chemotherapy, involved-field radiotherapy with 20 Gy followed.  
Because of renewed onset of nausea and vertigo after 3 weeks of treatment with ABVD and 4 weeks 
of treatment with steroids, a follow-up brain MRI was performed and demonstrated complete 
disappearance of the ‘vasculitic’ changes and no other pathologic findings. EEG was also normal. Five 
months after diagnosis and end of chemotherapy, the patient is in good health without any complaints  
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of nausea, emesis, vertigo or headache. Clinically and on PET-CT, there is no evidence of enlarged 
lymph nodes or metabolically active lymphoma. 
The patient has given his written informed consent for the case report to be published. 
Discussion 
Direct involvement of the CNS in Hodgkin’s lymphoma is rare, with an incidence of 
about 0.02%, and to our knowledge has never been described in NLPHL [1]. However, 
various paraneoplastic events in the nervous system, in particular the CNS, have been 
described in Hodgkin’s lymphoma patients and are summarized in table 1. 
Granulomatous angiitis and PCD are mainly reported in Hodgkin’s lymphoma as 
paraneoplastic events [9]. However, every other part of the nervous system can also be 
affected by paraneoplastic antibodies. Guillain-Barré syndrome and subacute 
polyradiculopathy have been reported in Hodgkin’s lymphoma and observed after 
allogeneic stem cell transplantation [10]. Denny-Brown syndrome (paraneoplastic 
subacute sensory neuropathy) is not common in Hodgkin’s lymphomas but mainly 
described in small cell lung cancer. It is associated with anti-Hu antibodies and is 
characterized by a severe inflammatory loss of the dorsal roots ganglia [11]. In a patient 
with thymic Hodgkin’s lymphoma, myasthenia gravis due to anti-AChR antibodies was 
described [12]. After successful treatment, remission of myasthenia occurred as well. 
Other antibodies against neural structures have been described in several case reports. To 
et al. [13] have found a 65 kD antibody against retinal protein that caused night blindness 
in a 24-year-old woman 1 week after initiation of chemotherapy for Hodgkin’s 
lymphoma. 
Our patient had an unclear neurological syndrome with presumed vasculitis on 
cerebral MRI. The differential diagnosis included PDC typically presenting with dizziness, 
nausea and vomiting, usually with acute onset and followed several days later by gait 
instability, oscillopsia, diplopia, ataxia, dysarthria and dysphagia [6, 7]. Possible causes of 
PDC are circulating anti-Tr and anti-mGluR1 antibodies destroying Purkinje cells in the 
cerebellum and leading to severe symptoms in particular ataxia [6, 7]. Our patient had 
several of these symptoms such as nausea, vomiting and vertigo, but no focal loss of 
neurological function was found on clinical examination. Patients with PDC typically 
present with a severe ataxia and cerebellar signs. We found neither pathologic Unterberg’s 
stepping test nor dysdiadochokinesia, other typical clinical signs of PDC, and laboratory 
testing further excluded this differential diagnosis since PCD-causing anti-Tr antibodies 
could not be found in serum or CSF, neither at diagnosis nor after treatment. Finally, 
MRI of our patient did not demonstrate any degeneration in the cerebellum. 
However, cerebral MRI showed perivascular bilateral infiltration of the temporal lobes 
consistent with vasculitis changes, presumably due to a paraneoplastic vasculitis, known 
in the literature as granulomatous angiitis [9]. The appearance of Hodgkin’s lymphoma 
and granulomatous angiitis of the CNS was first described in 1972 by Greco et al. [14]. 
They described the clinical course and complete remission after adequate chemotherapy. 
Furthermore, the authors suggested a possible association with varicella-zoster virus and 
the appearance of granulomatous angiitis in Hodgkin’s lymphoma. Paraneoplastic angiitis 
is extremely rare in Hodgkin’s lymphoma patients but has been described in a small series 
with poor outcome [9]. Rapid onset of therapy is necessary to avoid neurological 
complications including venous thrombosis or stroke [15]. Therapy of choice is steroids  
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and immediate lymphoma-directed chemotherapy. Long-term steroid therapy seems to 
be necessary in some patients to avoid recurrence of neurological symptoms [16]. 
In our patient, direct involvement of the CNS by Hodgkin’s lymphoma seems highly 
unlikely since normal liquor cytology was demonstrated and the patient is in continuous 
remission 5 months after diagnosis. It has to be stressed, however, that liquor cytology is 
not sensitive and specific enough to establish or rule out the diagnosis of direct CNS 
involvement of Hodgkin’s lymphoma. Gerstner et al. [4] analyzed a series of 16 cases of 
CNS Hodgkin’s lymphoma, and 9 of these 16 patients had lumbar puncture but only 2 
patients had atypical cells in liquor and just 1 had CD30 positive cells. On the other hand, 
to our knowledge there is no case of NLPHL documented with direct CNS involvement 
[1, 4]. 
In conclusion, we present the case of a 25-year-old patient with new onset epileptic 
seizures. Further examination demonstrated NLPHL stage II A and MRI showed cerebral 
vasculitis, most likely granulomatous angiitis. Because of the well-known poor outcome of 
this condition in the absence of rapid treatment, the patient was immediately treated with 
steroids and chemotherapy and is now in complete and enduring oncological and 
neurological remission 5 months after diagnosis. Patients with Hodgkin’s lymphoma and 
neurological symptoms of recent onset require urgent clinical work-up because the 
differential diagnosis is broad and includes several dangerous conditions. Direct CNS 
involvement is extremely rare but should be excluded by spinal tap or in unsecure cases 
by brain biopsy. Additional work-up depends on the clinical presentation, and in patients 
with ataxia, an anti-Tr antibody-positive PCD needs to be ruled out. Most importantly, 
treatment should be initiated rapidly in all patients with Hodgkin’s lymphoma and 
neurological symptoms.  
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Table 1. Paraneoplastic events in the nervous system in Hodgkin’s lymphoma patients 
Age Gen- 
der 
Diagnosis (symptoms)  Pathologic findings 
MRI, CT scanner 
CSF Lab  Treatment  Stage  Outcome  Reference 
23 F  paraneoplastic   
syndrome 
(paraparesis,  
sphincter dysfunction,  
nystagmus) 
basal ganglia,  
cerebellar tonsil,  
internal capsule,  
medulla spinae 
lymphocytosis, 
elevated protein 
normal ABVD,   
steroids, IVIG,  
plasmapheresis 
I A  persistent  
paraperesis 
Kalinka E. 
et al., 2002 
[17] 
53 M  paraneoplastic   
cerebellar ataxia  
(gait disturbance,  
cerebellar ataxia,  
downbeat nystagmus) 
none positive   
anti-Tr  
antibodies 
positive  
anti-Tr 
antibodies 
ABVD,  
radiation, IVIG, 
steroids,  
plasmapheresis 
n.a. neurology   
improved  
dramatically 
Taniguchi Y. 
et al., 2006 [6]
55 M  paraneoplastic  angiitis 
(transient right 
 hemiparesis, right  
upper limb  
ataxic monoparesis) 
recurrent cerebral 
venous thrombosis 
mild  
lymphozytosis 
normal rituximab  and 
steroids 
I A  improved  
symptoms 
Roggerone S. 
et al., 2008 
[15] 
52 M  granulomatous  angiitis 
(generalized  
tonic-clonic  
convulsion, confusion) 
confluent white  
matter change 
lymphocytic 
pleocytosis, 
elevated protein 
ESR  
21 mm/h  
CRP  
2.8 mg/l 
CTX, steroids  III A  no further  
seizures;  
confusion  
resolved 
Sheehy N. 
et al., 2003 
[18] 
26 F  granulomatous  angiitis 
(diplopia, nausea,  
emesis, headache,  
seizure-like episodes) 
areas of increased 
signaling in the  
parietal and  
temporal lobe 
lymphocytic 
pleocytosis, 
elevated protein 
n.a. ABVD,   
steroids, RTX 
I A  patient  
remained  
symptom- 
free for 2-year 
follow-up 
Delobel P. 
et al., 2004 
[19] 
ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; IVIG = intravenous immunoglobulin; CTX = chemotherapy; RTX = 
radiotherapy; n.a. = not available. 
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Fig. 1. a Pathologic findings in a cervical lymph node with nodular transformation with detectable 
typical L- and H-cells. PTGC = Progressive transformation of germinal centers. b Detailed view of 
typical L- and H-cells. c CD20 expression by L- and H-cells with negative T-cell rimming. d PD1-
positive T-cell rimming. These are typical immunohistochemical findings in NLPHL. 
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Fig. 2. a PET-CT with pathologically increased glucose metabolism in enlarged cervical lymph nodes. 
b PET-CT with metabolic remission after 2 cycles of ABVD chemotherapy (adriamycin, bleomycin, 
vinblastine and dacarabazine). 
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Fig. 3. Cerebral MRI scan with pathologic infiltration due to vasculitic change in both temporal lobes. 
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